S J Lubinga1, E Uwiduhaye. 1. Department of Pharmacy, Mbarara University of Science and Technology, Uganda. slubinga@must.ac.ug
Abstract
BACKGROUND: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions. The pharmacoepidemiology of such interactions in hospitals in Uganda is not known. OBJECTIVES: To determine the prevalence, clinical importance and factors associated with potential DDIs at Mbarara Regional Referral Hospital (MRRH), western Uganda. METHODS: Retrospective analysis of 235 randomly selected hospitalization episodes (medication charts and medical notes) from MRRH over a 1-year period from January to December 2008. We collected data on demographics, medications, principal diagnosis, co-morbid conditions and the length of hospital stay. Epocrates Rx® was used to identify and classify potential DDIs according to mechanism and management strategy. Descriptive statistics were generated and logistic regression used to determine associated factors. RESULTS: Overall prevalence of potential DDIs was approximately 23% (54 medication charts with at least one potential DDI out of 235 hospitalization episodes). Majority were postulated to occur through a pharmacodynamic mechanism (10.6%) and most required either "use with caution" (11.9%) or "modify treatment/monitor" (10.6%) as a suggested management strategy. After adjusting for confounders: age, sex, hospital department and number of co-morbid conditions, a principal diagnosis of a cardiovascular disease (OR 6.52 95% CI 1.32-32.14) and having 4 or more medicines on the chart (OR 4.30 95% CI 1.98-9.34) were associated with the presence of a potential DDI. CONCLUSION: Potential DDIs frequently occur at MRRH although most are not clinically significant. Patients with cardiovascular diseases and those who are prescribed multiple medications need to be monitored more closely.
BACKGROUND: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions. The pharmacoepidemiology of such interactions in hospitals in Uganda is not known. OBJECTIVES: To determine the prevalence, clinical importance and factors associated with potential DDIs at Mbarara Regional Referral Hospital (MRRH), western Uganda. METHODS: Retrospective analysis of 235 randomly selected hospitalization episodes (medication charts and medical notes) from MRRH over a 1-year period from January to December 2008. We collected data on demographics, medications, principal diagnosis, co-morbid conditions and the length of hospital stay. Epocrates Rx® was used to identify and classify potential DDIs according to mechanism and management strategy. Descriptive statistics were generated and logistic regression used to determine associated factors. RESULTS: Overall prevalence of potential DDIs was approximately 23% (54 medication charts with at least one potential DDI out of 235 hospitalization episodes). Majority were postulated to occur through a pharmacodynamic mechanism (10.6%) and most required either "use with caution" (11.9%) or "modify treatment/monitor" (10.6%) as a suggested management strategy. After adjusting for confounders: age, sex, hospital department and number of co-morbid conditions, a principal diagnosis of a cardiovascular disease (OR 6.52 95% CI 1.32-32.14) and having 4 or more medicines on the chart (OR 4.30 95% CI 1.98-9.34) were associated with the presence of a potential DDI. CONCLUSION: Potential DDIs frequently occur at MRRH although most are not clinically significant. Patients with cardiovascular diseases and those who are prescribed multiple medications need to be monitored more closely.
Authors: Matthijs L Becker; Marjon Kallewaard; Peter W J Caspers; Loes E Visser; Hubert G M Leufkens; Bruno H Ch Stricker Journal: Pharmacoepidemiol Drug Saf Date: 2007-06 Impact factor: 2.890
Authors: David V Espino; Oralia V Bazaldua; Raymond F Palmer; Charles P Mouton; Michael L Parchman; Toni P Miles; Kyriakos Markides Journal: J Gerontol A Biol Sci Med Sci Date: 2006-02 Impact factor: 6.053
Authors: Rachel P Riechelmann; Ian F Tannock; Lisa Wang; Everardo D Saad; Nathan A Taback; Monika K Krzyzanowska Journal: J Natl Cancer Inst Date: 2007-04-18 Impact factor: 13.506
Authors: Gabriel Kigen; Sylvester Kimaiyo; Winstone Nyandiko; Brian Faragher; Edwin Sang; Beatrice Jakait; Andrew Owen; David Back; Sara Gibbons; Kay Seden; Saye H Khoo Journal: PLoS One Date: 2011-02-23 Impact factor: 3.240
Authors: Prosperity C Eneh; Katherine Huppler Hullsiek; Daniel Kiiza; Joshua Rhein; David B Meya; David R Boulware; Melanie R Nicol Journal: BMC Infect Dis Date: 2020-08-05 Impact factor: 3.090